ViOptix公司研制出ODISsey无创组织血氧测量仪

一种新技术叫做光学弥散成像和分光光度计，允许开展无创伤、直接、实时地测定局部氧饱和度，而且费用低廉。新型组织血氧测定仪整合了这项技术，已经获得了美国食品药物管理局地许可。

新型血氧测定仪叫做ODISsey，是由ViOptix公司研制开发的，该公司是一家组织氧测定设备的开发商和制造商。新技术将做为诊断与监测设备，临床用途极为广泛。

ViOptix公司总裁兼首席执行官Mohamed Elmandjra指出：“对我们公司以及对无创性组织氧检测而言，这是一项重要成就。我们致力于发展各种创新产品，对健康保健市场具有极高的临床应用价值。食品药品管理局的许可对我们达到该目标是一个重要的里程碑。”

Novel Tissue Oximeter Technology
 
New technology called optical diffusion imaging and spectroscopy (ODIS) enables noninvasive, direct, real-time estimation of local tissue oxygen saturation (StO2) on a very cost-effective basis. A new tissue oximeter incorporating the technology has been cleared by the U.S. Food and Drug Administration (FDA).

The new oximeter is called ODISsey and was developed by ViOptix (Fremont, CA, USA), a developer and manufacturer of tissue oxygen measuring devices. The new technology will be used in diagnostic and monitoring equipment for a wide variety of clinical applications.

“This is a key achievement for us and for noninvasive tissue oxygen assessment in general,” noted Mohamed Elmandjra, president and CEO of ViOptix. “We are committed to bringing innovative products with high clinical value to the healthcare market, and FDA clearance is definitely a major milestone toward that goal.”